Healthcare / Medical DistributionASX
$0.67
-0.04 (-6.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-13.5M · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$84M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-63.5%
↓Gross Margin
13.3%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.4%
FCF CAGR
—
FCF margin
-116.4%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.7M · net income $-17.2M · FCF $-19.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.7M | $16.7M | $27.6M | $26.3M | $23.2M |
| Net Income | $-17.2M | $-17.2M | $-13.2M | $-4.7M | $-6.6M |
| EBITDA | $-16.0M | $-16.0M | $-11.6M | $-3.2M | $-5.0M |
| EPS | -0.16 | -0.16 | -0.13 | -0.05 | -0.07 |
| Gross Margin | 13.3% | 13.3% | 65.0% | 61.1% | 68.0% |
| Operating Margin | -202.6% | -202.6% | -52.7% | -38.1% | -32.9% |
| Net Margin | -103.2% | -103.2% | -47.9% | -17.8% | -28.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.19 | 0.13 | 0.12 |
| Current Ratio | 2.53 | 2.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-19.4M | $-19.4M | $-13.5M | $-7.7M | $-8.2M |
| Returns | |||||
| ROE | -63.5% | -63.5% | -30.9% | -14.6% | -18.1% |
| Valuation | |||||
| P/B | 2.70 | 2.70 | 3.85 | 5.50 | 3.68 |
| Growth & Yield | |||||
| Revenue Growth | -39.5% | -39.5% | 4.7% | 13.4% | — |
| EPS Growth | -21.9% | -21.9% | -153.1% | 29.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.13 → -0.16
Residual
-41.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.